ImmunoGen, Inc. to Present at Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 8, 2006--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that it will present at Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference, which is scheduled to take place June 14 - 15, 2006 at the New York Palace Hotel in New York City. The 25-minute presentation is to begin at 2:00 pm ET on Thursday, June 15, 2006, and will be given by Mitchel Sayare, ImmunoGen Chairman and CEO.
A live webcast of the presentation may be accessed through the "Investor Relations" section of the ImmunoGen website, www.immunogen.com. Afterwards, a replay of the presentation will be available at the same location until June 22, 2006.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Four TAP compounds are in clinical testing - huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, and AVE9633 and trastuzumab-DM1, which are in development by the sanofi-aventis Group and Genentech, respectively. The sanofi-aventis Group, Genentech, Centocor, Biogen Idec, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim, and Amgen (formerly Abgenix) have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with the sanofi-aventis Group.
CONTACT: Investors:
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
info@immunogen.com
SOURCE: ImmunoGen, Inc.
